Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 71.4% during trading on Tuesday . The company traded as high as C$0.12 and last traded at C$0.12. Approximately 592,088 shares traded hands during trading, an increase of 517% from the average daily volume of 95,938 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The company has a market cap of C$9.15 million, a PE ratio of -5.25 and a beta of 0.20. The stock’s 50-day moving average is C$0.08 and its 200 day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- The Risks of Owning Bonds
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- What is the S&P 500 and How It is Distinct from Other Indexes
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
- How to Invest in Small Cap Stocks
- These 3 Retail Stocks Can Keep Winning in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
